Literature DB >> 22991316

Enhanced MRI relaxivity of Gd(3+) -based contrast agents geometrically confined within porous nanoconstructs.

Richa Sethi1, Jeyarama S Ananta, Christof Karmonik, Meng Zhong, Steve H Fung, Xuewu Liu, King Li, Mauro Ferrari, Lon J Wilson, Paolo Decuzzi.   

Abstract

Gadolinium chelates, which are currently approved for clinical MRI use, provide relaxivities well below their theoretical limit, and they also lack tissue specificity. Recently, the geometrical confinement of Gd(3+) -based contrast agents (CAs) within porous structures has been proposed as a novel, alternative strategy to improve relaxivity without chemical modification of the CA. Here, we have characterized and optimized the performance of MRI nanoconstructs obtained by loading [Gd(DTPA)(H(2) O)](2-) (Magnevist®) into the pores of injectable mesoporous silicon particles. Nanoconstructs with three different pore sizes were studied, and at 60 MHz, they exhibited longitudinal relaxivities of ~24 m m(-1)  s(-1) for 5-10 nm pores and ~10 m m(-1)  s(-1) for 30 - 40 nm pores. No enhancement in relaxivity was observed for larger pores sizes. Using an outer-sphere compound, [GdTTHA](3-) , and mathematical modeling, it was demonstrated that the relaxivity enhancement is due to the increase in rotational correlation times (CA adsorbed on the pore walls) and diffusion correlation times (reduced mobility of the water molecules), as the pore sizes decreases. It was also observed that extensive CA adsorption on the outer surface of the silicon particles negates the advantages offered by nanoscale confinement. Upon incubation with HeLa cells, the nanoconstructs did not demonstrate significant cytotoxicity for up to 3 days post incubation, at different particle/cell ratios. In addition, the nanoconstructs showed complete degradation after 24 h of continuous agitation in phosphate-buffered saline. These data support and confirm the hypothesis that the geometrical confinement of Gd(3+) -chelate compounds into porous structures offers MRI nanoconstructs with enhanced relaxivity (up to 6 times for [Gd(DTPA)(H(2) O)](2-) , and 4 times for [GdTTHA](3-) ) and, potentially, improved stability, reduced toxicity and tissue specificity.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22991316      PMCID: PMC3846290          DOI: 10.1002/cmmi.1480

Source DB:  PubMed          Journal:  Contrast Media Mol Imaging        ISSN: 1555-4309            Impact factor:   3.161


  24 in total

Review 1.  Snapshot magnetic resonance imaging (Nobel lecture).

Authors:  Peter Mansfield
Journal:  Angew Chem Int Ed Engl       Date:  2004-10-18       Impact factor: 15.336

2.  Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents.

Authors:  Sophie Laurent; Luce Vander Elst; Robert N Muller
Journal:  Contrast Media Mol Imaging       Date:  2006 May-Jun       Impact factor: 3.161

Review 3.  Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.

Authors:  Peter Caravan
Journal:  Chem Soc Rev       Date:  2006-05-03       Impact factor: 54.564

4.  The association of silicon microparticles with endothelial cells in drug delivery to the vasculature.

Authors:  Rita E Serda; Jianhua Gu; Rohan C Bhavane; XueWu Liu; Ciro Chiappini; Paolo Decuzzi; Mauro Ferrari
Journal:  Biomaterials       Date:  2009-02-12       Impact factor: 12.479

5.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications.

Authors:  Ennio Tasciotti; Xuewu Liu; Rohan Bhavane; Kevin Plant; Ashley D Leonard; B Katherine Price; Mark Ming-Cheng Cheng; Paolo Decuzzi; James M Tour; Fredika Robertson; Mauro Ferrari
Journal:  Nat Nanotechnol       Date:  2008-03-02       Impact factor: 39.213

6.  Gold nanoparticles functionalized with gadolinium chelates as high-relaxivity MRI contrast agents.

Authors:  Loïck Moriggi; Caroline Cannizzo; Eddy Dumas; Cédric R Mayer; Alexey Ulianov; Lothar Helm
Journal:  J Am Chem Soc       Date:  2009-08-12       Impact factor: 15.419

Review 7.  Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers.

Authors:  Igor I Slowing; Juan L Vivero-Escoto; Chia-Wen Wu; Victor S-Y Lin
Journal:  Adv Drug Deliv Rev       Date:  2008-04-10       Impact factor: 15.470

8.  Impact of rigidification on relaxometric properties of a tricyclic tetraazatriacetic gadolinium chelate.

Authors:  Marc Port; Isabelle Raynal; Luce Vander Elst; Robert N Muller; Fabienne Dioury; Clotilde Ferroud; Alain Guy
Journal:  Contrast Media Mol Imaging       Date:  2006 May-Jun       Impact factor: 3.161

9.  Biodegradable luminescent porous silicon nanoparticles for in vivo applications.

Authors:  Ji-Ho Park; Luo Gu; Geoffrey von Maltzahn; Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  Nat Mater       Date:  2009-02-22       Impact factor: 43.841

10.  Glycoconjugates of gadolinium complexes for MRI applications.

Authors:  David A Fulton; Elisa M Elemento; Silvio Aime; Linda Chaabane; Mauro Botta; David Parker
Journal:  Chem Commun (Camb)       Date:  2006-02-08       Impact factor: 6.222

View more
  18 in total

1.  Impact of biopolymer matrices on relaxometric properties of contrast agents.

Authors:  Alfonso Maria Ponsiglione; Maria Russo; Paolo Antonio Netti; Enza Torino
Journal:  Interface Focus       Date:  2016-12-06       Impact factor: 3.906

2.  High signal contrast gating with biomodified Gd doped mesoporous nanoparticles.

Authors:  Wen-Yen Huang; Gemma-Louise Davies; Jason J Davis
Journal:  Chem Commun (Camb)       Date:  2012-11-19       Impact factor: 6.222

3.  Opportunities for NanoTheranosis in Lung Cancer and Pulmonary Metastasis.

Authors:  J Key; Y-S Kim; F Tatulli; A L Palange; B O'Neill; S Aryal; M Ramirez; X Liu; M Ferrari; R Munden; P Decuzzi
Journal:  Clin Transl Imaging       Date:  2014-10-01

4.  Hierarchically-Structured Magnetic Nanoconstructs with Enhanced Relaxivity and Cooperative Tumor Accumulation.

Authors:  Ayrat Gizzatov; Jaehong Key; Santosh Aryal; Jeyarama Ananta; Antonio Cervadoro; Anna Lisa Palange; Matteo Fasano; Cinzia Stigliano; Meng Zhong; Daniele Di Mascolo; Adem Guven; Eliodoro Chiavazzo; Pietro Asinari; Xuewu Liu; Mauro Ferrari; Lon J Wilson; Paolo Decuzzi
Journal:  Adv Funct Mater       Date:  2014-08-06       Impact factor: 18.808

Review 5.  Environmentally responsive MRI contrast agents.

Authors:  Gemma-Louise Davies; Iris Kramberger; Jason J Davis
Journal:  Chem Commun (Camb)       Date:  2013-10-28       Impact factor: 6.222

6.  Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer.

Authors:  Ayrat Gizzatov; Cinzia Stigliano; Jeyerama S Ananta; Richa Sethi; Rong Xu; Adem Guven; Maricela Ramirez; Haifa Shen; Anil Sood; Mauro Ferrari; Lon J Wilson; Xuewu Liu; Paolo Decuzzi
Journal:  Cancer Lett       Date:  2014-06-12       Impact factor: 8.679

Review 7.  The Emerging Role of Nanotechnology in Cell and Organ Transplantation.

Authors:  Ennio Tasciotti; Fernando J Cabrera; Michael Evangelopoulos; Jonathan O Martinez; Usha R Thekkedath; Malgorzata Kloc; Rafik M Ghobrial; Xian C Li; Alessandro Grattoni; Mauro Ferrari
Journal:  Transplantation       Date:  2016-08       Impact factor: 4.939

8.  Nano assembly and encapsulation; a versatile platform for slowing the rotation of polyanionic Gd(3+) -based MRI contrast agents.

Authors:  Annah Farashishiko; Kelly N Chacón; Ninian J Blackburn; Mark Woods
Journal:  Contrast Media Mol Imaging       Date:  2015-12-28       Impact factor: 3.161

Review 9.  Re-engineered imaging agent using biomimetic approaches.

Authors:  Tuyen Duong Thanh Nguyen; Ramesh Marasini; Santosh Aryal
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2021-10-26

10.  Design and Synthesis of Gold-Gadolinium-Core-Shell Nanoparticles as Contrast Agent: a Smart Way to Future Nanomaterials for Nanomedicine Applications.

Authors:  Fatima Aouidat; Sarah Boumati; Memona Khan; Frederik Tielens; Bich-Thuy Doan; Jolanda Spadavecchia
Journal:  Int J Nanomedicine       Date:  2019-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.